MUC16 and gastric cancer: Survival assays revealed that patients with the MUC16 mutation had longer overall survival (Figure 2(b), P = 4.380e − 3) and disease-free survival (P = 0.0444, Figure 2(c)), suggesting that the MUC16 mutation suppressed the developments of GC.